AuditLine › HHS OIG › Food and Drug Administration
HHS OIG recommendation 25-E-01-010.02
FDA should take steps to ensure appropriate documentation of meetings with sponsors in drug approval administrative files.
The recommendation, in the publisher's words
FDA should take steps to ensure appropriate documentation of meetings with sponsors in drug approval administrative files.
- Responsible agency
- Food and Drug Administration
- Issued
- January 7, 2025
- Report
- How FDA Used Its Accelerated Approval Pathway Raised Concerns in 3 of 24 Drugs Reviewed (OEI-01-21-00400) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Concur (as recorded by the publisher)
- Closed
- May 18, 2026 (publisher's date)
- Publisher topics
- Food; Drug and Device Safety, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
1 more, of which 0 are open in the publisher's file.
- FDA should define specific factors that would require FDA's accelerated approval council to advise on certain drug applications.HHS OIG 25-E-01-010.01 · issued Jan 7, 2025 · closed May 18, 2026Closed Unimplemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.